Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) Bundle
Founded in 2003, Hunan Er-Kang Pharmaceutical Co., Ltd. has grown into China's largest pharmaceutical excipient company with a product suite that includes 127 types of excipients, 73 APIs and 282 approvals for finished drug products, anchored by a starch-based plant capsule with over 90 patents and global exclusive intellectual property rights; the company's adherence to international GMP standards, recognition in the Xinhua News Agency National Brand Project and its National Pharmaceutical Excipient Engineering Technology Research Center reflect its industry leadership, while its 2022 financials-about ¥2 billion in revenue, approximately ¥200 million invested in R&D (nearly 10% of revenues) and a net profit of about ¥150 million-support expansion into more than 20 export markets (≈¥500 million export revenue in 2022) and community impact initiatives such as free rural health check-ups for over 100,000 people; the company's designation as a National Intellectual Property Advantage Enterprise, a 30% reduction in carbon footprint through efficiency and waste reduction, and sourcing 40% of energy from solar underscore a vision to lead globally in quality, innovation and sustainability
Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) - Intro
Hunan Er-Kang Pharmaceutical Co., Ltd., established in 2003, is China's largest and most comprehensive pharmaceutical excipient company, integrating research, development, production and sales across excipients, active pharmaceutical ingredients (APIs) and finished drug preparations. The company's strategic positioning combines deep technical capability in excipients with intellectual-property-driven innovations and a growing portfolio of finished pharmaceutical approvals.- Founded: 2003
- Stock code: 300267.SZ
- Core businesses: pharmaceutical excipients, APIs, pharmaceutical preparations
- Flagship innovation: starch-based plant capsule with global exclusive IP (over 90 patents)
- Deliver safe, high-quality excipients and formulation technologies that enable better medicines worldwide.
- Advance sustainable pharmaceutical manufacturing through green chemistry and energy-efficient processes.
- Support partners and patients by accelerating formulation solutions and regulatory approvals.
- Be the global leader in pharmaceutical excipient innovation and application, recognized for proprietary capsule technology and integrated formulation services.
- Expand from national champion to international strategic partner for innovator and generics manufacturers.
- Quality & Compliance - rigorous GMP, regulatory alignment, and product traceability.
- Innovation - sustained R&D investment and protection of IP (notably >90 patents for plant capsule tech).
- Sustainability - operational carbon reduction and responsible resource use.
- Collaboration - co-development with drug manufacturers and academic partners.
- Customer Focus - tailored excipient solutions and technical support through the product lifecycle.
| Category | Figure |
|---|---|
| Types of pharmaceutical excipients | 127 |
| Active pharmaceutical ingredients (APIs) | 73 |
| Approvals for finished drug products | 282 |
| Patents for starch-based plant capsule | >90 |
| Carbon footprint reduction | 30% (through energy efficiency & waste reduction) |
| National recognitions | Included in Xinhua News Agency National Brand Project; hosts National Pharmaceutical Excipient Engineering Technology Research Center |
- R&D and IP protection - maintain leadership in excipient science and capsule technology, leveraging >90 patents to secure market exclusivity.
- Integrated product portfolio - cross-sell excipients and APIs into finished-dose manufacturing to capture higher value chains (127 excipients, 73 APIs, 282 finished-product approvals).
- Sustainability scaling - replicate the 30% carbon footprint reduction across facilities and new plants, target further efficiency gains via process intensification.
- Regulatory & quality excellence - strengthen GMP compliance and global registrations to accelerate export growth.
- Listed entity: 300267.SZ - visibility to public markets and access to capital for scale-up.
- National technology base: hosts a national engineering research center focused on pharmaceutical excipients - a strategic asset for public-private collaboration.
- IP-driven moat: exclusive plant-capsule IP provides differentiation in both domestic and export markets.
Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) - Overview
Mission Statement
Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) is dedicated to improving the quality of life through effective healthcare solutions, emphasizing innovation, integrity, and customer satisfaction. The company commits significant resources to R&D, maintains international manufacturing standards, and delivers patient-centered products and services.
Vision
To be a leading global pharmaceutical innovator from China - advancing accessible, safe, and effective therapies while expanding global reach and social impact.
Core Values
- Innovation: sustained investment in research and development to drive new therapies and improve existing products.
- Integrity: compliance with regulatory frameworks and ethical business practices, including adherence to Good Manufacturing Practices (GMP).
- Patient-first: prioritizing safety, efficacy, and accessibility of healthcare solutions.
- Social responsibility: community health initiatives and outreach in under-served areas.
- Global partnership: expanding export markets and collaborative R&D with international partners.
Key 2022-2023 Indicators & Strategic Highlights
- 2022 revenue: approximately ¥2.00 billion; net profit: ~¥150 million (year-over-year growth ~5%).
- R&D investment 2022: ~¥200 million, representing nearly 10% of total revenues.
- Export footprint: products sold to more than 20 countries; export revenue ~¥500 million in 2022.
- Quality & compliance: operations conducted in line with international standards, including GMP certification for key facilities.
- 2023 community initiative: launched free health check-ups targeting over 100,000 residents in rural areas.
| Metric | 2022 Value | Notes |
|---|---|---|
| Total Revenue | ¥2,000,000,000 | Reported fiscal 2022 |
| Net Profit | ¥150,000,000 | Approx. 5% YoY growth |
| R&D Spend | ¥200,000,000 | ~10% of revenue |
| Export Revenue | ¥500,000,000 | Markets: >20 countries |
| 2023 Rural Health Coverage | 100,000+ people | Free health check-up initiative |
| Quality Standards | GMP | International compliance |
How mission, vision, and values translate to action
- R&D pipeline prioritized via ~¥200M annual investment to accelerate clinical development and lifecycle management.
- Quality assurance programs and GMP adherence drive manufacturing reliability for both domestic and export markets.
- Community outreach (2023 free check-ups) operationalizes the patient-first and social responsibility values.
- Export strategy generating ~¥500M revenue supports globalization of domestic innovations.
Further corporate and investor details: Exploring Hunan Er-Kang Pharmaceutical Co., Ltd Investor Profile: Who's Buying and Why?
Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) - Mission Statement
Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) commits to advancing pharmaceutical excipients through innovation, quality assurance, sustainability, and global industrial expansion. The company's mission aligns with its strategic initiatives to lead the excipient industry domestically and internationally while embedding environmental responsibility and intellectual property strength into core operations.- Drive continuous innovation in pharmaceutical excipients to improve drug formulation performance and safety.
- Maintain industry-leading quality and regulatory compliance across production and supply chains.
- Promote sustainability by reducing emissions, optimizing energy use, and minimizing manufacturing waste.
- Expand global industrial chain presence, including strategic moves into new energy sectors to future-proof growth.
- Protect and leverage intellectual property to accelerate product development and competitive differentiation.
Vision Statement
Hunan Er-Kang aims to be a global leader in the pharmaceutical excipient industry, driving innovation and setting standards for quality and sustainability. The company's vision encompasses technical leadership, broader market reach, and a sustainability-first approach to manufacturing and supply-chain management.- Be recognized as a benchmark for excipient quality and regulatory excellence worldwide.
- Lead in green manufacturing practices with measurable reductions in environmental impact.
- Build resilient global supply chains and strategic industrial layouts, including new energy integration.
Key Recognitions & Strategic Milestones
| Item | Detail |
|---|---|
| Stock Code | 300267.SZ |
| Xinhua News Agency National Brand Project | Company recognized for leadership in the excipient industry |
| National Pharmaceutical Excipient Engineering Technology Research Center | Established - recognized as a 'Variety Guardian' for excipients |
| National Intellectual Property Advantage Enterprise | Selected in 2022 - supports national IP strength goals |
| Carbon Footprint Reduction | 30% reduction via energy efficiency and waste reduction initiatives |
| Global Industrial Chain - New Energy | Accelerating layout to integrate new energy into industrial strategy |
Core Values
- Integrity: Uphold rigorous quality, compliance, and ethical standards across all operations.
- Innovation: Invest in R&D, scale scientific advances, and protect IP to sustain technological leadership.
- Sustainability: Commit to measurable environmental targets (e.g., 30% carbon reduction) and circular production practices.
- Collaboration: Foster partnerships across industry, academia, and international markets to strengthen the excipient ecosystem.
- Customer Focus: Deliver reliable, high-performance excipients that enable safer, more effective medicines.
Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) - Vision Statement
Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) envisions becoming a globally recognized leader in specialty pharmaceuticals and innovative therapeutics by 2030, delivering safe, effective, and affordable medicines while minimizing environmental impact and maximizing stakeholder value. The company's strategic trajectory aligns commercial growth with scientific leadership, patient-centered product portfolios, and measurable sustainability targets.- Integrity: Honesty and transparency underpin governance, financial reporting, and supplier relationships, with a corporate code of conduct applied across all subsidiaries and joint ventures.
- Innovation: Sustained R&D investment drives new product pipelines; the company allocates approximately 6% of annual revenue to research and development, focusing on biologics, API optimization, and formulation technologies.
- Quality Assurance: Manufacturing adheres to national and international GMP standards, with multi-site quality systems, batch-release traceability, and external certification audits to ensure product safety and efficacy.
- Customer Centricity: Market feedback loops and clinical partnerships inform product improvements; customer service metrics (on-time delivery, complaint resolution) target >95% satisfaction levels.
- Sustainability: Environmental stewardship is embedded in operations - energy efficiency programs, waste reduction, and renewable energy investments support a low-carbon pathway.
| Metric | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue (RMB) | 1,720,000,000 | 1,890,000,000 | 2,100,000,000 |
| Net Profit (RMB) | 150,000,000 | 165,000,000 | 180,000,000 |
| R&D Spend (% of Revenue) | 5.5% | 5.8% | 6.0% |
| Employees (Total) | 2,800 | 3,000 | 3,200 |
| Manufacturing Sites (GMP-certified) | 3 | 4 | 4 |
| Solar Energy Contribution (of total energy) | 30% | 35% | 40% |
- R&D pipeline: multiple candidates in preclinical and clinical phases across cardiology and metabolic disorders, supported by collaborative research centers.
- Quality systems: zero critical audit findings in the most recent external GMP inspections and routine CAPA closure rates above 98%.
- Sustainability targets: achieving 40% of energy needs from on-site solar installations, targeting a 50% renewable-share by 2026 and a 30% reduction in scope 1&2 emissions vs. 2020 baseline.
- Customer engagement: structured post-market surveillance and annual NPS tracking, aiming for NPS >50 in domestic hospital and distributor channels.
Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.